Despite the numerous efforts of randomized studies on advanced gastric cancer, no globally
accepted standard regimen has yet been established. Two triplet regimens have already …

There are still remarkable disparities in the treatment of gastric cancer between the East and
West. Treatment outcomes for this disease have improved in Japan due to early detection …

In the era of targeted therapy based on genomic alterations, the treatment strategy for
metastatic colorectal cancer (mCRC) has been changing. Before systemic treatment initiation, …

Background Trastuzumab, a monoclonal antibody against human epidermal growth factor
receptor 2 (HER2; also known as ERBB2), was investigated in combination with …

Background VEGFR-2 has a role in gastric cancer pathogenesis and progression. We assessed
whether ramucirumab, a monoclonal antibody VEGFR-2 antagonist, in combination with …

Importance Therapeutic options are needed for patients with advanced gastric cancer whose
disease has progressed after 2 or more lines of therapy. Objective To evaluate the safety …

Background Early clinical trials conducted primarily in Japan have shown that TAS-102, an
oral agent that combines trifluridine and tipiracil hydrochloride, was effective in the treatment …

… Ohtsu et al … Shah, Eric Van Cutsem, Sun Young Rha, Akira Sawaki, Sook Ryun Park,
Ho Yeong Lim, Yasuhide Yamada, Jian Wu, Yoon-Koo Kang Collection and assembly of …

Background Patients with advanced gastric or gastro-oesophageal junction cancer that
progresses on chemotherapy have poor outcomes. We compared pembrolizumab with paclitaxel …

Background The best chemotherapy regimen for metastatic gastric cancer is uncertain, but
promising findings have been reported with irinotecan plus cisplatin and S-1 (tegafur, 5-chloro…